logo
logo

Psilera And Usf Collaborators At Morsani College Of Medicine Receive Additional Funding To Support Preclinical Studies On New Chemical Entities

Psilera And Usf Collaborators At Morsani College Of Medicine Receive Additional Funding To Support Preclinical Studies On New Chemical Entities

03/08/22, 8:17 AM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgtampa
Psilera Inc. ("Psilera"), a biotechnology company specializing in the clinical development of psychedelic-inspired compounds and drug delivery systems for treating mental health disorders, was granted more than $130,000 from the Florida High Tech Corridor's Matching Grants Research Program, effectively doubling the life of a study conducted in collaboration with researchers from the University of South Florida ("USF"). This preclinical study focuses on understanding Psilera's non-hallucinogenic N,N-dimethyltryptamine (DMT) derivatives and their therapeutic potential to treat mood and addiction disorders.

Company Info

Company
Psilera
Location
tampa, florida, united states
Additional Info
Psilera is a leading biotechnology company developing proprietary neuromodulators based on traditionally psychoactive compounds targeting mental health disorders. Psilera's next-generation data platform is being used to identify lead compounds with modified psychedelic and therapeutic effects in mood, cognitive, and substance use disorders. New formulations tailoring the therapeutic effects of DMT will improve treatment scalability and patient compliance, further expanding addressable markets. Psilera leverages a world-class scientific and pharmaceutical executive team to repurpose psychoactive natural products into effective and accessible patient-centric treatments.